<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04458285</url>
  </required_header>
  <id_info>
    <org_study_id>20191025</org_study_id>
    <nct_id>NCT04458285</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Sacubitril/Valsartan in Maintenance Hemodialysis Patients With Heart Failure</brief_title>
  <acronym>ESARHD-HF</acronym>
  <official_title>A Multi-center, Randomized, Open-label, Active-controlled, 12-week Study to Evaluate the Efficacy and Safety of Sacubitril/Valsartan in Maintenance Hemodialysis Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Provincial People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sacubitril/valsartan reduces the risk of cardiovascular mortality among patients with heart
      failure with reduced ejection fraction, and has been recently indicated as a new treatment
      option with a strong level of recommendation (class I, level of evidence B) in the main
      international guidelines. Cardiovascular disease (CVD) is the most common cause of death in
      end stage renal disease (ESRD) patients undergoing hemodialysis (HD). Hence, treatments to
      improve mortality and specifically cardiovascular outcomes in this population are greatly
      needed. So far, no data available about the efficacy and safety of sacubitril/valsartan in
      ESRD patients undergoing hemodialysis, although this medication was noted to be effective and
      comparably well tolerable in those with estimated glomerular filtration rate(eGFR) 20 to 60
      mL/min/1.73 m2 in the United Kingdom Heart and Renal Protection-III trial.

      The purpose of this open label, randomized controlled study with prospective data collection
      is to assess the efficacy and safety of sacubitril/valsartan in maintenance hemodialysis
      patients with heart failure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular ejection fraction (LVEF)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline in left ventricular ejection fraction (LVEF) between baseline and end of study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>N terminal pro B type natriuretic peptide (NT-prpBNP)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood samples will be collected for analysis of concentration of N terminal pro B type natriuretic peptide (NT-proBNP) every 2 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular end diastolic volume (LVEDV)</measure>
    <time_frame>12 weeks</time_frame>
    <description>LVEDV is measured as baseline and after 12 weeks follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left atrial volume (LAV)</measure>
    <time_frame>12 weeks</time_frame>
    <description>LAV is measured as baseline and after 12 weeks follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The ratio of mitral early diastolic blood flow peak and mitral annulus velocity (E/E')</measure>
    <time_frame>12 weeks</time_frame>
    <description>E/E' is measured as baseline and after 12 weeks follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Artery Pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Pulmonary Artery Pressure is measured as baseline and after 12 weeks follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of high-sensitivity serum troponin T</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood samples will be collected for analysis of concentration of serum troponin every 4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA functional classification</measure>
    <time_frame>12 weeks</time_frame>
    <description>NYHA functional classification is assessed from baseline and 12 weeks follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minnesota Heart Failure Quality of Life Questionnaire (LiHFe)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in health status is assessed using the disease-specific Minnesota Heart Failure Quality of Life Questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic and diastolic blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Systolic and diastolic blood pressure will be measured every 2 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of postassium</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood samples will be collected for analysis of concentration of postassium every 2 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram(ECG)</measure>
    <time_frame>12 weeks</time_frame>
    <description>ECG QT Interval analysis was performed at baseline and 12 weeks follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate(eGFR)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in estimated glomerular filtration rate(eGFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Angioedema</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidence of Angioedema during the study period 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of alanine aminotransferase or aspartate aminotransferase</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood samples will be collected for analysis of concentration of alanine aminotransferase or aspartate aminotransferase every 2 weeks.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Neprilysin</measure>
    <time_frame>12 weeks</time_frame>
    <description>The concentration of Neprilysis is measured by Human Neprilysin ELISA Kit as baseline and after 12 weeks follow-up.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Hemodialysis Complication</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Sacubitril/valsartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in experimental group will receive sacubitril/valsartan with the recommended starting dose: 50mg twice daily (if previous angiotensin converting enzyme inhibitor(ACEI), ensure 36-hour washout period), after 2-4 weeks, the dose will be doubled to the target maintenance dose of 100mg twice daily(if tolerated) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benazepril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in active comparator group will receive Benazepril with an dose of 10 mg once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacubitril / Valsartan Oral Tablet [Entresto]</intervention_name>
    <description>Patients in experimental group will receive sacubitril/valsartan with the recommended starting dose: 50mg twice daily (if previous ACEI, ensure 36-hour washout period), after 2-4 weeks, the dose will be doubled to the target maintenance dose of 100mg twice daily(if tolerated) for 12 weeks.</description>
    <arm_group_label>Sacubitril/valsartan</arm_group_label>
    <other_name>LCZ696 100 mg tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benazepril 10mg Tablet</intervention_name>
    <description>Patients in active comparator group will receive Benazepril with an dose of 10 mg once daily.</description>
    <arm_group_label>Benazepril</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained before any study assessment is performed.

          -  End stage renal disease (ESRD) patients (eGFR&lt;15ml/min/1.73m² as measured by the
             Chronic Kidney Disease Epidemiology Collaboration formula at screening) who have been
             receiving hemodialysis 3 times a week for at least 12 weeks before registration.

          -  Chronic heart failure (NYHA class ≥ II) with reduced ejection fraction, defined as
             known LVEF ≤ 40%.

          -  Mean sitting systolic blood pressure(msSBP)≥140 mmHg.

          -  Use of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker for at
             least 2 weeks.

          -  Good compliance.

        Exclusion Criteria:

          -  Acute renal failure with hemodialysis.

          -  Isolated right heart failure owing to pulmonary disease, primary cause of dyspnea due
             to noncardiac, non-HF causes such as acute or chronic respiratory disorders.

          -  Systolic blood pressure lower than 100 mmHg at screening (&lt;95 mmHg at the
             randomization visit).

          -  Previous history of intolerance to recommended target doses of angiotensin receptor
             blockers.

          -  Significant laboratory abnormalities at screening interfering with assessment of study
             drug safety or efficacy (such as serum potassium&gt;5.5 or &lt;3.5mmol/L, serum
             sodium&lt;130mmol/L or alanine aminotransferase or aspartate aminotransferase&gt;2 times the
             upper limit of the normal range)

          -  History of hypersensitivity to any of the study drugs or their excipients or to drugs
             of similar chemical classes.

          -  History of angioedema.

          -  Any medications that have potential for drug-drug interaction with LCZ696 will not be
             allowed during the study.

          -  Pregnant female.

          -  Use of sacubitril/valsartan prior to week-2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuangxin Liu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Provincial People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Faye Jiang, Doctor</last_name>
    <phone>(+86)020-83525210</phone>
    <email>gdphgcp@gdph.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuangxin Liu, Doctor</last_name>
      <phone>(+86)13543456446</phone>
      <email>13543456446@139.com</email>
    </contact>
    <investigator>
      <last_name>Shuangxin Liu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li Zhang, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhonglin Feng, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sijia Li, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhuo Li, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Feng Wen, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lei Fu, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jianchao Ma, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30.</citation>
    <PMID>25176015</PMID>
  </reference>
  <reference>
    <citation>Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A, Bowman L, Brunskill N, Cockwell P, Hill M, Kalra PA, McMurray JJV, Taal M, Wheeler DC, Landray MJ, Baigent C. Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. Circulation. 2018 Oct 9;138(15):1505-1514. doi: 10.1161/CIRCULATIONAHA.118.034818.</citation>
    <PMID>30002098</PMID>
  </reference>
  <reference>
    <citation>Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E; PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11. Erratum in: N Engl J Med. 2019 Mar 14;380(11):1090.</citation>
    <PMID>30415601</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 26, 2020</study_first_submitted>
  <study_first_submitted_qc>July 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangdong Provincial People's Hospital</investigator_affiliation>
    <investigator_full_name>ShuangXin Liu</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <keyword>Sacubitril/valsartan</keyword>
  <keyword>Benazepril</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Benazepril</mesh_term>
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

